Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) traded up 3.7% during mid-day trading on Tuesday . The stock traded as high as $29.54 and last traded at $29.43. 132,275 shares changed hands during trading, an increase of 2% from the average session volume of 129,142 shares. The stock had previously closed at $28.39.
Analysts Set New Price Targets
Separately, Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd.
Get Our Latest Research Report on Galapagos
Galapagos Price Performance
Institutional Investors Weigh In On Galapagos
Several hedge funds have recently bought and sold shares of the stock. Quadrant Capital Group LLC lifted its position in Galapagos by 18.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 261 shares during the period. Headlands Technologies LLC lifted its stake in Galapagos by 56.7% in the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 446 shares in the last quarter. Rhumbline Advisers increased its position in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 814 shares during the last quarter. Signaturefd LLC lifted its position in Galapagos by 78.6% during the fourth quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 867 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of Galapagos in the 4th quarter worth $44,000. 32.46% of the stock is currently owned by institutional investors.
Galapagos Company Profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
See Also
- Five stocks we like better than Galapagos
- The Most Important Warren Buffett Stock for Investors: His Own
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- What Is WallStreetBets and What Stocks Are They Targeting?
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What is Put Option Volume?
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.